Fractyl Health FY2029 EPS Estimate Boosted by HC Wainwright

Fractyl Health, Inc. (NASDAQ:GUTS) – HC Wainwright lifted their FY2029 earnings per share estimates for shares of Fractyl Health in a research report issued on Wednesday, March 25th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn $0.37 per share for the year, up from their prior estimate of $0.31. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health’s FY2030 earnings at $0.94 EPS.

GUTS has been the subject of several other research reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fractyl Health in a research note on Monday, December 29th. Finally, Morgan Stanley lowered Fractyl Health from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $8.00 to $2.00 in a research note on Thursday, January 29th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $5.40.

Fractyl Health Stock Up 16.2%

Shares of GUTS stock opened at $0.50 on Thursday. Fractyl Health has a 12-month low of $0.38 and a 12-month high of $3.03. The firm has a 50-day moving average price of $0.76 and a 200 day moving average price of $1.29. The company has a market capitalization of $68.52 million, a P/E ratio of -0.27 and a beta of 1.51.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.34.

Institutional Trading of Fractyl Health

A number of institutional investors have recently made changes to their positions in GUTS. Jane Street Group LLC bought a new stake in Fractyl Health during the 2nd quarter worth about $31,000. FNY Investment Advisers LLC bought a new stake in Fractyl Health in the third quarter valued at approximately $31,000. Scientech Research LLC acquired a new stake in Fractyl Health during the 3rd quarter valued at $49,000. Prelude Capital Management LLC acquired a new stake in shares of Fractyl Health during the 3rd quarter worth about $55,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Fractyl Health during the third quarter worth approximately $56,000.

Key Fractyl Health News

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: Q4 results and EPS beat — Fractyl reported Q4 EPS of $0.15, topping the consensus loss estimate and surprising investors; management also released a formal press release with the fourth‑quarter and full‑year 2025 results. Fractyl press release
• Positive Sentiment: Clinical/program progress highlighted — Management emphasized Revita program updates in its shareholder materials and investor commentary, which supports long‑term company value if development milestones continue. Revita progress note
• Positive Sentiment: After‑hours jump and elevated volume — News coverage (MSN) notes a ~21% after‑hours move following the release, and intraday volume ran above average, signaling strong short‑term interest and trade activity. MSN after‑hours coverage
• Positive Sentiment: Short‑interest reduction reported earlier in March — Data showed a sizable drop in reported short interest to ~5.8% of float as of March 13, which can reduce downward pressure and support upside on positive news. (Market data entries)
• Neutral Sentiment: Earnings call transcript — The full Q4 2025 earnings call provides detailed commentary on cash runway, costs and strategic priorities; investors will parse guidance and cadence for future milestones. Earnings call transcript
• Neutral Sentiment: Analyst/coverage summaries — Yahoo and other outlets summarized the quarter and noted financial challenges; the tone is mixed—beat this quarter but still operational/financial questions remain. Yahoo summary
• Negative Sentiment: Ongoing financial and volatility risks — Despite the EPS beat, Wall‑Street consensus still models negative EPS for the fiscal year and the stock trades well below its 50‑ and 200‑day averages; liquidity, cash runway and execution on Revita remain key risk factors for the share price.
• Negative Sentiment: Conflicting short‑interest data — Several data feeds show inconsistent/erroneous short‑interest figures (zero/NaN entries), increasing uncertainty about true short positioning and potential for volatile squeezes or covering spikes that can exaggerate moves in either direction.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.